Interleukin-1-receptor antagonist in type 2 diabetes mellitus.
By C. Larsen, Mirjam V. Faulenbach, A. Vaag, A. Vølund, J. Ehses, B. Seifert, T. Mandrup-Poulsen, M. Donath. New England Journal of Medicine, 2007
943 citations recorded by the source corpus.
Subfields: Epidemiology, Genetics, Surgery
View Paper: https://www.semanticscholar.org/paper/870dea598d8f1d9c171f9f7c450a1a176c04699f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Genetics
In Surgery
Citations in the corpus
- Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. (2014, background): “[67] Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, et al.”
- Type 2 diabetes as an inflammatory disease (2011, background): “Most pro-inflammatory factors that are present at high levels in the blood of patients with T2D are IL-1 dependent, and blocking IL-1 activity has been shown to reduce their concentration”
- The IL-1 family: regulators of immunity (2010, background): “Although not a subject of this Review, which focuses on the immunological actions of IL-1 family members, there is also excitement around the potential for IL-1 inhibition in treating type 2 diabetes, resulting from a new understanding of the role of IL-1 in controlling pancreatic islet β-cell proli”
- Anti-inflammatory Agents: Present and Future (2010, neutral): “, 2009) Type 2 Diabetes (Donath et al., 2009; Larsen et al., 2009; Larsen et al., 2007) Smoldering Multiple Myeloma (Lust et al.”
- Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes (2020, background): “A clearer reduction of HbA1c, comparing this to the previous study on T2D (Larsen et al., 2007), can be explained based on the theory that pathogenic mechanisms of T2D could be exaggerated in the context of RA.”
- An Overview of Nrf2 Signaling Pathway and Its Role in Inflammation (2020, background): “Another report demonstrated that the improvement of insulin secretion and protection in type-2 diabetes was associated with the suppression of IL-1 and IL-1 receptor [157].”